HOME >> MEDICINE >> NEWS
Gene therapy boosts cancer chemotherapy

Researchers at the University of Chicago have found a way to combine cancer chemotherapy with gene therapy designed to disrupt the growth of blood vessels to a tumor. The combination, tested in mice, is far more effective than standard chemotherapy and has no additional side effects. This innovative approach is described in the August issue of the Journal of Clinical Investigation.

This new approach evolved out of a similar system, now entering phase-2 human trials, that combines gene therapy with radiation therapy.

"The radiation therapy approach appears to be quite effective, aiming a powerful anticancer arsenal at the tumor," said Ralph Weichselbaum, M.D., professor and chairman of radiation oncology at the University of Chicago and director of the study. "The new combination with chemotherapy, however, not only enables us to target the original tumor but also potentially to aim at the small clusters of cancer cells that may have spread to distant sites."

The therapy uses a modified cold virus to insert the gene for tumor necrosis factor (TNF) into cells within a tumor. TNF is a potent biological substance that can kill cancer cells directly and disrupt their blood supply, but it can be very toxic when given systemically. The researchers originally altered the TNF gene so that it could be turned on by radiation therapy. Now they have produced a version of the gene that can be activated by exposure to the common anti-cancer drug cisplatin. So mice treated with both the gene injections and cisplatin have high concentrations of TNF within the injected tumors, but nowhere else.

The researchers found that the combined therapy was far more effective than either cisplatin or TNF-gene injections alone. Tumors treated with the combination of gene therapy and cisplatin had "significant regression," note the authors, with "no additional toxicity."

Untreated tumors doubled in size within four days and grew to more th
'"/>

Contact: John Easton
jeaston@uchospitals.edu
773-702-6241
University of Chicago Medical Center
5-Aug-2002


Page: 1 2

Related medicine news :

1. Study shows patch therapy may be as effective as oral medications
2. Novel therapy tested in mice could chase away cat allergies
3. Drug therapy may be comparable to invasive cardiac procedures for elderly patients with heart attack
4. Risk of cardiac death after radiotherapy for breast cancer has declined, study finds
5. Antiretroviral therapy may prevent excess risk of some cancers in people with HIV
6. Bevacizumab combined with chemotherapy prolongs survival for some patients with advanced lung cancer
7. Breakthrough in medical research: New chemotherapy gives hope to brain tumour patients
8. Two years after gene therapy treatments, severe angina patients showed prolonged clinical benefit
9. Combining PET and CT scans leads to more accurate radiation therapy for lung cancer patients
10. Cognitive behavioral therapy and medication is effective in the treatment of panic disorder
11. Study finds drug eluting stents as effective as vascular brachytherapy in preventing restenosis

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Gene therapy boosts cancer chemotherapy

(Date:5/21/2013)... 2013 Standard advice for mattress shoppers ... else. However given industry’s less than exceptional satisfaction ratings ... the internet, Consumer Mattress Reports sets out to revise ... Best Mattress .” , This article addresses several components ... that may not be readily apparent to many shoppers. ...
(Date:5/21/2013)... 2013 DISCcert has served the training ... use 17 DISC applications at the July 25 & ... , The July 25 & 26th DISC certification in ... of applying DISC. The time-tested, proven support materials will ... DISC training materials ; worksheets, handouts, learning ...
(Date:5/21/2013)... 2013 Parker Waichman LLP, a national ... injured by defective medical devices, is addressing new research ... on May 15, 2013. The study found that magnetic ... that occur in patients with metal-on-metal hip implants even ... ) , “We’ve known for quite ...
(Date:5/21/2013)... France: The Orsiro stent, which is a novel ... demonstrated non-inferiority to the Xience Prime everolimus-eluting stent ... lumen loss at nine months in the results ... today. , The BIOFLOW-II substudy used intravascular ultrasound ... assess neointimal hyperplasia and stent apposition at nine ...
(Date:5/21/2013)... (PRWEB) May 21, 2013 Phoseon Technology ... at the 20th Annual IMI European Ink Jet ... proven market leader, Phoseon continues to invest in product ... the adoption of UV LED curing in printing applications. ... families on the market offering both air cooled and ...
Breaking Medicine News(10 mins):Health News:Choosing the Best Mattress Simplified in Consumer Mattress Reports’ Latest Article 2Health News:DISCcert Offers 17 Applications in Coming DISC Certification 2Health News:DISCcert Offers 17 Applications in Coming DISC Certification 3Health News:DISCcert Offers 17 Applications in Coming DISC Certification 4Health News:Parker Waichman LLP Comments on New Study Showing that MRI is Useful for Predicting Failure of Metal-on-Metal Hip Implants 2Health News:Parker Waichman LLP Comments on New Study Showing that MRI is Useful for Predicting Failure of Metal-on-Metal Hip Implants 3Health News:Biodegradable stent proves non-inferior to drug-eluting stent 2
(Date:5/21/2013)... and TARRYTOWN, N.Y. , May ... SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced ... published online the positive Phase 2a study results of ... is an investigational monoclonal antibody targeting the alpha subunit ... signaling of both IL-4 and IL-13, drivers of Th2 ...
(Date:5/21/2013)... UNION CITY, Calif. , May 21, 2013 /PRNewswire/ ... manufacturing point-of-care blood analysis systems, announced today that ... will present at the Stifel Annual Dental & Veterinary ... ET. The conference will be held at Le Parker ... . About Abaxis Abaxis develops, ...
(Date:5/21/2013)... May 21, 2013 Reportlinker.com announces ... available in its catalogue:   ... Scenario for Medical Devices in the US ...   Changing Regulatory and Reimbursement ... Market   Summary ...
Breaking Medicine Technology:Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 2Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 3Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 4Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 5Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 6Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 7Abaxis, Inc. to Present at the Stifel Annual Dental & Veterinary Conference 2Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market 2Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market 3Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market 4
Cached News: